Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma-Reference-Cited by-同舟云学术

Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma

Published:2019-10 Issue:10 Volume:12 Page:1314-1322
ISSN:1936-5233
Container-title:Translational Oncology
language:en
Short-container-title:Translational Oncology

Author:

Hanaford Allison R.,Alt Jesse,Rais Rana,Wang Sabrina Z.,Kaur Harpreet,Thorek Daniel L.J.,Eberhart Charles G.,Slusher Barbara S.,Martin Allison M.,Raabe Eric H.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference50 articles.

1. Metabolism and action of amino acid analog anti-cancer agents;Ahluwalia;Pharmacol Ther,1990

2. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups;Archer;Cancer cell,2018

3. Targeting Metabolism as a Novel Therapeutic Approach to Autoimmunity, Inflammation, and Transplantation;Bettencourt;J Immunol,2017

4. Amino Acid transporters in cancer and their relevance to "glutamine addiction": novel targets for the design of a new class of anticancer drugs;Bhutia;Cancer Res,2015

5. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study;Bowers;J Clin Oncol,2006

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glutamine and leukemia research: progress and clinical prospects;Discover Oncology;2024-08-31

2. Targeting the glutamine-arginine-proline metabolism axis in cancer;Journal of Enzyme Inhibition and Medicinal Chemistry;2024-07-25

3. VISTA Emerges as a Promising Target against Immune Evasion Mechanisms in Medulloblastoma;Cancers;2024-07-24

4. CTPS1 inhibition synergizes with replication stress signaling inhibition inMYC-amplified Group 3 medulloblastoma;2024-06-04

5. Targeting O-GlcNAcylation in cancer therapeutic resistance: The sugar Saga continues;Cancer Letters;2024-04